Evidence map›Paper›PMID 24270505›Full record

Observational studyBMJ (Clinical research ed.)2013

Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records.

J K Quint, E Herrett, K Bhaskaran, A Timmis, H Hemingway, J A Wedzicha, L Smeeth

Registry-linked trialOpen access · hybridAbstract readObservational StudyVideo-Audio Media
In one paragraph

Observational study in BMJ (Clinical research ed.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01335672 (Survival After First Myocardial Infarction in Patients With and Without Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01335672 completednot on this map

Survival After First Myocardial Infarction in Patients With and Without Chronic Obstructive Pulmonary Disease

TypeobservationalSponsorLondon School of Hygiene and Tropical MedicineRan2011 to 2014Enrolled2,100,000ConditionsMyocardial Infarction, Chronic Obstructive Pulmonary Disease
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Metoprolol for the Prevention of Acute Exacerbations of COPD.The New England journal of medicine · 2019
    Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. COPD and acute myocardial infarction.European respiratory review : an official journal of the European Respiratory Society · 2020
    Review
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

J K QuintDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
E Herrett
K Bhaskaran
A Timmis
H Hemingway
J A Wedzicha
L Smeeth
London School of Hygiene & Tropical Medicine · GBLondon Chest Hospital · GBThe Royal Free Hospital · GBUniversity College London · GB

Funding

British Heart FoundationCancer Research UKDepartment of Health PDF-2011-04-007Department of Health RP-PG-0407-10314Medical Research Council G0902135Medical Research Council MR/K006584/1Wellcome Trust 086091/Z/08/ZWellcome Trust 098504
6 · The paper itself

Abstract

objectivesTo investigate whether the use and timing of prescription of β blockers in patients with chronic obstructive pulmonary disease (COPD) having a first myocardial infarction was associated with survival and to identify factors related to their use.

designPopulation based cohort study in England.

settingUK national registry of myocardial infarction (Myocardial Ischaemia National Audit Project (MINAP)) linked to the General Practice Research Database (GPRD), 2003-11.

participantsPatients with COPD with a first myocardial infarction in 1 January 2003 to 31 December 2008 as recorded in MINAP, who had no previous evidence of myocardial infarction in their GPRD or MINAP record. Data were provided by the Cardiovascular Disease Research using Linked Bespoke studies and Electronic Health Records (CALIBER) group at University College London.

main outcome measureCox proportional hazards ratio for mortality after myocardial infarction in patients with COPD in those prescribed β blockers or not, corrected for covariates including age, sex, smoking status, drugs, comorbidities, type of myocardial infarction, and severity of infarct.

resultsAmong 1063 patients with COPD, treatment with β blockers started during the hospital admission for myocardial infarction was associated with substantial survival benefits (fully adjusted hazard ratio 0.50, 95% confidence interval 0.36 to 0.69; P<0.001; median follow-up time 2.9 years). Patients already taking a β blocker before their myocardial infarction also had a survival benefit (0.59, 0.44 to 0.79; P<0.001). Similar results were obtained with propensity scores as an alternative method to adjust for differences between those prescribed and not prescribed β blockers. With follow-up started from date of discharge from hospital, the effect size was slightly attenuated but there was a similar protective effect of treatment with β blockers started during hospital admission for myocardial infarction (0.64, 0.44 to 0.94; P=0.02).

conclusionsThe use of β blockers started either at the time of hospital admission for myocardial infarction or before a myocardial infarction is associated with improved survival after myocardial infarction in patients with COPD. REGISTRATION: NCT01335672.

Indexed as

RegistriesAdrenergic beta-AntagonistsAgedAged, 80 and overCohort StudiesDisease-Free SurvivalElectronic Health RecordsFemaleHumansMaleMiddle AgedMyocardial InfarctionPropensity ScoreProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveTreatment OutcomeAdrenergic beta-Antagonists

Identifiers

PMID24270505
PMCPMC3898388
OpenAlexW2089921224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.